Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sonomed's ophthalmic scans:

This article was originally published in Clinica

Executive Summary

The Chinese FDA has approved Sonomed's PacScan and E/Z-Scan ophthalmic imaging products. Sonomed, a New York-based subsidiary of Escalon Medical, plans to market the products there immediately, through the Hwa-In Group and Shenzhen K&K, its existing distributors in China. The E/Z-Scan series, approved in the US in 2004, consists of B-scan and A/B-scan ultrasound systems, which are used to image and diagnose retinal and other conditions at the back of the eye. The PacScan series is made up of A-scans, pachymeters and combination systems used in cataract and refractive surgery. Pachymeters measure the thickness of the cornea and can also be used to screen patients suspected of developing glaucoma. Both systems are widely marketed internationally, Escalon said, but declined to give details of where.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT046717

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel